LifeSci Capital Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $22
Protara Therapeutics: Promising Clinical Progress and Strong Buy Rating Amid Encouraging ADVANCED-2 Study Results
Scotiabank Initiates Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $12
Protara Therapeutics Analyst Ratings
Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target
LifeSci Capital Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $22
Protara Therapeutics' TARA-002 Shows Promising Potential in NMIBC Treatment, Justifying Buy Rating
LifeSci Capital Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $22
Cantor Fitzgerald Initiates Protara Therapeutics(TARA.US) With Buy Rating
Protara Therapeutics Initiated at Overweight by Cantor Fitzgerald
LifeSci Capital Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $22
LifeSci Capital Initiates Coverage On Protara Therapeutics With Outperform Rating, Announces Price Target of $22
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $30
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $23
Protara Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Protara Therapeutics' TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $23
Protara Therapeutics Analyst Ratings